New hope for hodgkin lymphoma: drug combo could replace chemo in relapsed patients
NCT ID NCT07572123
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This clinical trial is for people whose Hodgkin lymphoma has returned or not responded to first treatment. It has two parts: one for standard-risk patients testing a combination of targeted drugs (brentuximab vedotin and nivolumab) plus radiation, and another for high-risk patients testing the immunotherapy pembrolizumab after a stem cell transplant. The goal is to see if these approaches work better than the usual high-dose chemotherapy and transplant. About 374 participants aged 5 to 75 will take part across multiple centers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- brentuximab vedotin, nivolumab, pembrolizumab
- What this could lead to
- If successful, this could offer more effective and less toxic treatment options for people with relapsed Hodgkin lymphoma, potentially improving survival without the need for intensive chemotherapy.
- What could go wrong
- This is a mid-stage trial (Phase 2/3) that hasn't started recruiting yet. The new combinations may not prove better than standard care, and side effects from immunotherapy or radiation could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CLASSIC HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to outsmart resistant hodgkin lymphoma
- Can an old drug make immunotherapy work again for hodgkin lymphoma?
- HIV cancer hope: immune combo shows early promise but trial halted
- New combo tackles tough lymphomas
- Experimental combo therapy shows promise for Tough-to-Treat lymphomas
- Triple-Drug attack on tough hodgkin lymphoma shows promise in early trial